Just saw ADMA Biologics announced a $200 mln capital return plan and honestly this is pretty solid for shareholders. They're doing a $125 mln accelerated share repurchase with JPMorgan, which means they're getting serious about returning cash. The deal structure is interesting - they're buying back shares at $15.57 from late February, and already received about 6.4 mln shares in early March representing 80% of the total purchase. CEO Adam Grossman basically said they've got strong revenue growth, better margins, and more cash flow coming in, so they can both invest in growth AND return capital to investors at the same time. That's the kind of position you want to see a biopharma company in. Combined with their prior repurchases since May 2025, they've now bought back around $160 mln worth of stock. Stock was trading at $15.88 in pre-market when this news dropped, up almost 2%. Not shocking given the positive cash flow signal, but shows the market's paying attention to these mln-dollar capital allocation moves.